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stable on clozapine. Between examinations there will be no planned inter-
ference with the antipsychotic treatment, but antipsychotic treatment may 
be changed during the period in the intention to improve symptoms.
The primary longitudinal outcome is comparing changes in BBB-
permeability along with symptom-fluctuations. This will be done by 
comparing changes in qAlb, which is the gold standard technique meas-
uring the CSF:serum albumin ratio (QAlb).
Results: The study has been approved by the regional ethical committee and 
data collection will begin in 2020.
Discussion: We expect the obtained results will contribute to a better path-
ophysiological understanding about illness markers and their progression 
over time and in relation to functional outcome.
T11. CORONARY ARTERY CALCIFICATION IN 
PEOPLE WITH SCHIZOPHRENIA
Trine Trab*1, René Ernst Nielsen1, Jens Broendum Froekjaer1, 
Svend Eggert Jensen1
1Aalborg University Hospital
Background: Coronary artery disease (CAD) is one of the major causes of 
premature mortality in patients with schizophrenia. Coronary artery calci-
fication (CAC) is an independent predictor of cardiac mortality and CAD 
in the general population, but has not yet been investigated in patients with 
schizophrenia. The aim of the present study is to compare CAC quantified 
by cardiac computed tomography (CT) in patients with schizophrenia to 
the general population.
Methods: Baseline data from an ongoing prospective cohort study including 
200 patients with schizophrenia (ICD-10 diagnoses F20 or F25) diagnosed 
at least 10  years prior to inclusion (chronic group) and 86 patients with 
schizophrenia diagnosed within two years prior to inclusion (debut group). 
Patients in the debut group were matched 1:1 on age, gender and smoking 
status with psychiatrically healthy controls (PHC). All participants under-
went cardiac CT and the CAC was quantified using Agatston Score. Mean 
CAC in the chronic group was compared to reference CAC scores whilst 
mean CAC in the debut group was compared to PHC. Information on car-
diovascular risk factors, illness history, social and psychiatric conditions 
were obtained at baseline.
Results: Data is currently being analyzed and results will be presented at the 
Congress of International Schizophrenia Research Society.
Discussion: If  the CAC quantified by CT in patients with schizophrenia 
differs from the PHC population, it might act as a tool for early detection 
of CAD in these patients. Thus, the findings of this study might contribute 
to preventive strategies in order to decrease cardiovascular mortality.
T12. THE RELATIONSHIP OF INTESTINAL 
PERMEABILITY FACTORS WITH 
SOCIODEMOGRAPHIC AND PHYSICAL 
HEALTH FACTORS AND PANSS SCORES IN 
SCHIZOPHRENIA PATIENTS AND HEALTHY 
CONTROLS
Jenny Borkent*1, Iris E. C. Sommer1,  
Bartholomeus C. M. Haarman1
1University Medical Center Groningen
Background: Recent studies have pointed to the gut-brain axis as a new 
venue for treatment of psychiatric disorders, with increased inflamma-
tion stemming from increased intestinal permeability to further affect 
brain functioning in a significant subset of patients. Yet, this line of re-
search is still in its infancy, with multiple studies showing increased intes-
tinal permeability in schizophrenia and bipolar disorders, demonstrated 
as translocation of food and bacterial antigens, as well as intestinal 
microbiome disturbances.
Methods: Therefore, we measured intestinal permeability markers soluble 
CD14 (sCD14) and lipopolysaccharide binding protein (LBP) in schizo-
phrenia patients and healthy controls. Intestinal permeability markers were 
compared to several sociodemographic, including age, gender and BMI, and 
physical health variables, including CRP, glucose, cholesterol, triglycerides, 
HDL, LDL and non-HDL, and Positive and Negative Syndrome Scale 
(PANSS) scores. Of the control group (n = 43), 76.7% was male, with a 
mean age of 25.1 years. Of the schizophrenia group (n = 105) 75.2 % was 
male, with a mean age of 27.4 years and an average PANSS score of 57.2.
Results: Levels of LBP and sCD14 were not significantly different between 
schizophrenia patients and controls. LBP and sCD14 levels were neither 
correlated in the control group, nor in the schizophrenia group. In the control 
group Females had elevated LBP levels compared to males (p < 0.01), but 
not in the schizophrenia group. Quantitative levels of LBP, but not sCD14, 
correlated with triglycerides in the schizophrenia group (R2 = 0.049, p < 
0.05). Furthermore, quantitative levels of sCD14, but not LBP, correlated 
with CRP in the schizophrenia group (R2 = 0.078, p < 0.05). Finally, LBP 
levels in patients correlated with PANSS negative scores (R2 = 0.055, p < 
0.05). Neither a correlation of LBP and sCD14 with age, nor with BMI was 
observed in both the control and the schizophrenia group.
Discussion: In conclusion, these intestinal permeability markers showed 
few differences between the schizophrenia and the control group. We found 
weak, yet significant correlations with triglycerides, CRP and severity of 
negative symptoms, which may be caused by poor eating habits or metabolic 
syndrome leading to leaky gut in the more severely affected patients. These 
results are not in line with results of Severance et al. (2013), who performed 
a similar analysis and found differences in intestinal permeability markers 
between a control group and a schizophrenia group. Furthermore, they did 
observe a positive correlation between sCD14 and LBP in both the con-
trol and the schizophrenia group. The difference between that study and 
our current findings may stem from the different patients samples, as we 
assessed patients in their first five years after diagnosis, when metabolic syn-
drome was less abundant.
T13. CORNEAL CONFOCAL MICROSCOPY 
DETECTS NEURAL CHANGES IN 
SCHIZOPHRENIA
Peter Woodruff*1, Georgios Ponirakis2, Reem Ghandi1,  
Amani Hussein1, Anjushri Bhagat1, Ioannis Petropoulos2,  
Adnan Khan2, Hoda Gad2, Ahmed Aly Al Sotouhy3,  
Ahmed Own3, Surjith Vattoth3, Marwan Ramadan2,  
Hanadi Al Hamad,4, James Currie1, Rayaz A Malik2
1Academic Health System- Mental Health, Hamad Medical 
Corporation; 2Weil Cornell Medical College- Qatar; 3Neuroscience 
Institute, Hamad Medical Corporation; 4Hamad Medical 
Corporation
Background: A combination of neurodevelopmental and degenerative 
neural changes are likely to underpin positive and negative symptoms in 
schizophrenia. However, there are currently no validated biomarkers to ac-
curately quantify the extent of neural changes in schizophrenia.
Corneal confocal microscopy (CCM) is a non-invasive ophthalmic imaging 
technique that has been used to demonstrate in vivo corneal nerve fiber 
abnormalities in a range of peripheral neuropathies and central neurode-
generative disorders including Parkinson’s disease, multiple sclerosis and 
dementia.
We wished to test the hypothesis that corneal nerve abnormalities occur in 
patients with schizophrenia, particularly those with negative symptoms and 
cognitive impairment.
Methods: Patients with DSM-V schizophrenia without other causes of pe-
ripheral neuropathy other than metabolic syndrome underwent assessment 
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